1. Home
  2. MSGS vs CELC Comparison

MSGS vs CELC Comparison

Compare MSGS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madison Square Garden Sports Corp. (New)

MSGS

Madison Square Garden Sports Corp. (New)

HOLD

Current Price

$367.75

Market Cap

8.0B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$91.18

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSGS
CELC
Founded
1879
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.0B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
MSGS
CELC
Price
$367.75
$91.18
Analyst Decision
Buy
Strong Buy
Analyst Count
9
9
Target Price
$341.29
$112.56
AVG Volume (30 Days)
284.0K
1.8M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.52
$720.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$188.60
$12.48
52 Week High
$397.00
$151.02

Technical Indicators

Market Signals
Indicator
MSGS
CELC
Relative Strength Index (RSI) 49.99 35.47
Support Level $320.66 $83.77
Resistance Level $397.00 $99.52
Average True Range (ATR) 11.02 6.26
MACD -3.41 -0.38
Stochastic Oscillator 27.13 45.86

Price Performance

Historical Comparison
MSGS
CELC

About MSGS Madison Square Garden Sports Corp. (New)

Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: